Famitinib Malate

DRUG3 trials

Sponsors

Fudan University, Jiangsu HengRui Medicine Co., Ltd., Hunan Cancer Hospital

Conditions

Breast NeoplasmsCervical CancerHealthy Adult Subjects

Phase 1

A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers

CompletedNCT04400123

Jiangsu HengRui Medicine Co., Ltd.Healthy Adult Subjects

Start: 2020-05-27End: 2020-07-18Updated: 2021-10-22

Phase 2

A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer

CompletedNCT01653574

Fudan UniversityBreast Neoplasms

Start: 2012-05-31End: 2013-11-30Updated: 2013-12-03

Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

Not yet recruitingNCT07627620

Hunan Cancer HospitalCervical Cancer

Start: 2026-06-30End: 2029-03-30Target: 54Updated: 2026-06-04